Kobori T, Onishi Y, Yoshida Y, Tahara T, Kikuchi T, Kubota T, et al
Future randomized controlled trials should further validate these findings on vascular health in larger, more diverse hypertensive populations
AI Clinical Sandbox Rigorous QA on every submission
* Correspondence: Jie Li [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
While monthly GLP-1 formulations may become commercially available soon in higher-income regions, other geographies especially those with high expected biosimilar penetration may continue relying on weekly-dosed drugs for the foreseeable future